Emily Rosenich
YOU?
Author Swipe
View article: Ante-mortem cognitive trajectories associated with Aβ and tau biomarker profiles in older adults with cerebrovascular disease: a longitudinal cohort study
Ante-mortem cognitive trajectories associated with Aβ and tau biomarker profiles in older adults with cerebrovascular disease: a longitudinal cohort study Open
Background Beta-amyloid (Aβ) plaques and tau tangles are pathological hallmarks of Alzheimer’s disease (AD); however, autopsy studies reveal that most older adults also present with cerebrovascular disease (CVD) markers. It remains unclear…
View article: A clinician implementation protocol for BetterBrains: An online, person‐centred risk factor management program to prevent cognitive decline
A clinician implementation protocol for BetterBrains: An online, person‐centred risk factor management program to prevent cognitive decline Open
Objective Modifiable risk factors, particularly those in midlife, can contribute to cognitive decline and dementia. Despite this, the ‘how’ of dementia risk reduction, including the application of interventional and care frameworks to deli…
View article: Associations between BDNF Val66Met and tau‐PET and episodic memory performance in sporadic AD
Associations between BDNF Val66Met and tau‐PET and episodic memory performance in sporadic AD Open
Background In the presence of abnormally high amyloid (Aβ+), carriage of the brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism Met allele (Met66) is associated with faster clinical disease progression, greater neuronal loss an…
View article: Demographic, clinical and Alzheimer’s disease risk characteristics associated with interest in <i>APOE</i> disclosure amongst middle‐aged Australian adults
Demographic, clinical and Alzheimer’s disease risk characteristics associated with interest in <i>APOE</i> disclosure amongst middle‐aged Australian adults Open
Background Clinical guidelines in Australia discourage disclosure of apolipoprotein E ( APOE ) genotypes but advances in Alzheimer’s disease (AD) therapeutics will likely change this. Limited work has assessed interest in APOE disclosure i…
View article: Learning deficits in late middle‐aged <i>APOE</i> ε4 carriers: Implications for emergent Alzheimer’s disease
Learning deficits in late middle‐aged <i>APOE</i> ε4 carriers: Implications for emergent Alzheimer’s disease Open
Background Recent studies suggest learning deficits are the earliest cognitive abnormality to emerge in Alzheimer’s disease (AD). Using the Online Repeatable Cognitive Assessment‐Language Learning Test (ORCA‐LLT), cognitively unimpaired (C…
View article: Baseline demographic, risk and cognitive characteristics of the final randomized sample enrolled in a decentralised multi‐domain lifestyle intervention trial (BetterBrains) to delay cognitive decline
Baseline demographic, risk and cognitive characteristics of the final randomized sample enrolled in a decentralised multi‐domain lifestyle intervention trial (BetterBrains) to delay cognitive decline Open
Background The BetterBrains Trial is a prospective behavior‐modification blinded endpoint randomized controlled trial to delay cognitive decline in middle‐aged adults (aged 40‐70) with a family history of dementia. The primary outcome is a…
View article: Associations between BDNF Val66Met and tau‐PET and episodic memory performance in sporadic AD
Associations between BDNF Val66Met and tau‐PET and episodic memory performance in sporadic AD Open
Background In the presence of abnormally high amyloid (Aß+), carriage of the brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism Met allele (Met66) is associated with faster clinical disease progression, greater neuronal loss an…
View article: <i>BDNF</i> Val66Met moderates episodic memory decline and tau biomarker increases in early sporadic Alzheimer’s disease
<i>BDNF</i> Val66Met moderates episodic memory decline and tau biomarker increases in early sporadic Alzheimer’s disease Open
Objective Allelic variation in the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has been shown to moderate rates of cognitive decline in preclinical sporadic Alzheimer’s disease (AD; i.e., Aβ + older adults), and pre-symp…
View article: Associations between multidomain modifiable dementia risk factors with AD biomarkers and cognition in middle-aged and older adults
Associations between multidomain modifiable dementia risk factors with AD biomarkers and cognition in middle-aged and older adults Open
This study aimed to determine associations between modifiable dementia risk factors (MDRF), across domains mood symptomatology, lifestyle behaviors, cardiovascular conditions, cognitive/social engagement, sleep disorders/symptomatology, wi…
View article: Ante‐mortem cognitive trajectories of older adults with cerebrovascular disease across Aβ and tau biomarker profiles determined at autopsy in the National Alzheimer’s Coordinating Center database
Ante‐mortem cognitive trajectories of older adults with cerebrovascular disease across Aβ and tau biomarker profiles determined at autopsy in the National Alzheimer’s Coordinating Center database Open
Background Alzheimer’s disease (AD) is characterised biologically by beta‐amyloid (Aβ) plaques and tau tangles, but autopsy studies reveal that most older adults also present with cerebrovascular disease (CVD) markers. Effects of biologica…
View article: The effect of <i>BDNF</i> Val66Met on memory, CSF total‐tau, CSF ptau<sub>181</sub> and CSF Aβ<sub>42</sub> in early sporadic Alzheimer’s disease
The effect of <i>BDNF</i> Val66Met on memory, CSF total‐tau, CSF ptau<sub>181</sub> and CSF Aβ<sub>42</sub> in early sporadic Alzheimer’s disease Open
Background Allelic variation in the brain‐derived neurotrophic factor ( BDNF ) Val66Met polymorphism has been shown to moderate rates of cognitive decline in preclinical sporadic Alzheimer’s disease (i.e., Aβ+ older adults), and pre‐sympto…
View article: The BetterBrains Trial: Baseline characteristics and trial progress of an online multi‐domain lifestyle intervention trial to delay cognitive decline in middle‐aged adults at risk of dementia
The BetterBrains Trial: Baseline characteristics and trial progress of an online multi‐domain lifestyle intervention trial to delay cognitive decline in middle‐aged adults at risk of dementia Open
Background BetterBrains is a prospective, blinded endpoint, 24‐month randomised controlled trial (RCT). It aims to test the effectiveness of an online, person‐centred, modifiable risk factor (RF) management program in delaying cognitive de…
View article: Synergistic contributions of vascular risk factors and <i>APOE</i> ε4 carriage to cognitive performance in middle‐aged adults enrolled in the Healthy Brain Project
Synergistic contributions of vascular risk factors and <i>APOE</i> ε4 carriage to cognitive performance in middle‐aged adults enrolled in the Healthy Brain Project Open
Background Midlife vascular risk factors (VRFs) and APOE ε4 carriage are individually associated with poor cognitive performance and increased dementia risk. However, the extent to which VRFs interact with APOE ε4 carriage to influence cog…
View article: How Modifiable Are Modifiable Dementia Risk Factors? A Framework for Considering the Modifiability of Dementia Risk Factors
How Modifiable Are Modifiable Dementia Risk Factors? A Framework for Considering the Modifiability of Dementia Risk Factors Open
Many risk factors for dementia, identified from observational studies, are potentially modifiable. This raises the possibility that targeting key modifiable dementia risk factors may reduce the prevalence of dementia, which has led to the …
View article: BDNF Val66Met moderates increases in CSF t-tau and p-tau181 in early sporadic Alzheimer’s disease: A prospective cohort study
BDNF Val66Met moderates increases in CSF t-tau and p-tau181 in early sporadic Alzheimer’s disease: A prospective cohort study Open
Background: Allelic variation in the brain-derived neurotrophic factor ( BDNF ) Val66Met polymorphism has been shown to moderate rates of cognitive decline in preclinical sporadic Alzheimer’s disease (i.e., Aβ+ older adults), and pre-sympt…
View article: Participant characteristics, modifiable dementia risk, and associated goal setting within a large online, multi‐domain, risk factor management program (BetterBrains) to delay cognitive decline
Participant characteristics, modifiable dementia risk, and associated goal setting within a large online, multi‐domain, risk factor management program (BetterBrains) to delay cognitive decline Open
Background In 40% of cases, dementia can be attributed to potentially modifiable risk factors (RFs) such as poor vascular health, poor sleep, low mood, and low social/cognitive engagement. 1 BetterBrains (betterbrains.org.au) is a prospect…
View article: Modifiable dementia risk factors are associated with greater subjective cognitive concerns but not perceived susceptibility to dementia in late middle‐aged adults: Baseline characteristics of the BetterBrains Trial
Modifiable dementia risk factors are associated with greater subjective cognitive concerns but not perceived susceptibility to dementia in late middle‐aged adults: Baseline characteristics of the BetterBrains Trial Open
Background A range of lifestyle factors in midlife can increase risk for developing dementia in late‐life. 1 However, it remains unclear whether the presence of such risk factors (RFs) is associated with individuals’ insight into their ris…
View article: Multidomain modifiable dementia risk factors are associated with poorer cognition in midlife.
Multidomain modifiable dementia risk factors are associated with poorer cognition in midlife. Open
These findings may suggest that multidomain MDRFs are highly frequent in middle-aged adults and are related to poorer cognition. This supports that modifiable dementia risk is multidimensional and raises the possibility that multidomain be…
View article: Lots of ‘breakthroughs’, still no cure. Do the new dementia drugs bring us any closer?
Lots of ‘breakthroughs’, still no cure. Do the new dementia drugs bring us any closer? Open
View article: Validation of a digit symbol substitution test for use in supervised and unsupervised assessment in mild Alzheimer’s disease
Validation of a digit symbol substitution test for use in supervised and unsupervised assessment in mild Alzheimer’s disease Open
The DSST-Meds showed good construct and criterion validity when used in both supervised and unsupervised contexts and provided a strong foundation to investigate the utility of the DSST in groups with low familiarity to neuropsychological …
View article: Differential Effects of <i>APOE</i> and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in Aβ− and Aβ+ Older Adults
Differential Effects of <i>APOE</i> and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in Aβ− and Aβ+ Older Adults Open
These results are consistent with studies showing that increasing age and APOE ε4 are associated with increased rates of HV loss and EM decline. In Aβ- CN adults, lower prevalence of modifiable cardiovascular risk factors was associ…
View article: The relationship between cognitive engagement and better memory in midlife
The relationship between cognitive engagement and better memory in midlife Open
Introduction Engagement in cognitively stimulating work and activities may slow cognitive decline and dementia. We examined the individual and combined associations of four cognitive engagement indices (educational attainment, occupational…
View article: Cognitive Reserve as an Emerging Concept in Stroke Recovery
Cognitive Reserve as an Emerging Concept in Stroke Recovery Open
Stroke is a leading cause of death and disability. It is a complex and largely heterogeneous condition. Prognosis for variations in impairment and recovery following stroke continues to be challenging and inaccurate, highlighting the need …
View article: Unstable world: Recent experience affects spatial perception
Unstable world: Recent experience affects spatial perception Open